Dentium (A145720) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 was KRW 159.1 billion, with 2Q25 revenue at ₩82.3 billion, both reflecting significant year-over-year declines due to demand contraction and competition.

• Operating income for H1 2025 was KRW 25.1 billion, with 2Q25 at ₩15.5 billion, and net income for H1 2025 was KRW 17.4 billion, with 2Q25 at ₩4.7 billion, all showing sharp drops.

• Main product lines, including implants and regeneration, experienced significant sales declines.

• The company maintains a strong global presence, with 24 consolidated subsidiaries and 80% of sales from overseas markets.

Financial highlights

• Gross margin improved to 65.8% in 2Q25 and was 54.1% for H1 2025, both up year-over-year despite lower sales.

• Operating margin was 18.9% in 2Q25, down from 24.8% in 2Q24.

• Cash and cash equivalents at June 30, 2025, were KRW 82.0 billion, down from KRW 99.6 billion at year-end 2024.

• SG&A expenses decreased 6% year-over-year, but the SG&A ratio rose by 10.8 percentage points to 46.9%.

• Dividend payout for H1 2025 was KRW 5.2 billion, with a payout ratio of 7.1%.

Outlook and guidance

• Demand recovery in China remains limited due to ongoing market downturn and regulatory uncertainty.

• Modest sales growth expected in Vietnam and other Asian markets in the second half.

• The company is expanding into the hydrogen fuel cell business, with commercial production expected after 2026.

• Dental segment remains the core business, but diversification into energy is expected to drive future growth.

• Gradual sales recovery anticipated domestically after 4Q.